Hormonal
Sustained nutritional ketosis achieved through a continuous remote care intervention (CCI) involving carbohydrate restriction (<30g/day initially) leads to significant improvements in glycemic control, weight loss, and diabetes remission in Type 2 Diabetes patients over 2 years, while reducing medication dependence without adverse effects on bone health.
To manage Type 2 Diabetes long-term, consider a continuous care approach that includes nutritional ketosis. Start with less than 30g of carbs per day, aiming for a blood ketone level of 0.5-3.0 mmol/L. Work with a healthcare team to monitor your progress and adjust medications as needed. This approach has been shown to improve blood sugar, reduce weight, and even reverse diabetes in many cases over 2 years, without harming bone health.
The CCI group sustained long-term beneficial effects on multiple clinical markers of diabetes and cardiometabolic health at 2 years while utilizing less medication. The intervention was also effective in the resolution of diabetes and visceral obesity with no adverse effect on bone health.
Why this rating
The study is a non-randomized, open-label, controlled trial with a relatively large sample size (262 CCI vs 87 UC) and long duration (2 years), but lacks randomization and blinding.
Source
Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial
Shaminie J. Athinarayanan et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00348
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →